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Abstract: Sepsis is a complex systemic inflammatory syndrome, the most common cause of which
is attributed to systemic underlying bacterial infection. The complete mechanisms of the dynamic
pro- and anti-inflammatory processes underlying the pathophysiology of sepsis remain poorly
understood. Natural killer (NK) cells play a crucial role in the pathophysiology of sepsis, leading to
exaggerated inflammation due their rapid response and production of pro-inflammatory cytokines
such as interferon gamma (IFN-γ). Several studies have already shown that NK cells undergo
lymphopenia in the peripheral blood of patients with sepsis. However, our understanding of the
mechanisms behind its cellular trafficking and its role in disease development is restricted to studies in
animal models. In this study, we aimed to compare the human NK cell subset (CD56bright or dim) levels
in the peripheral blood and bronchoalveolar lavage (BAL) fluid of sepsis patients. We conducted a
case-control study with a sample size consisting of 10 control patients and 23 sepsis patients enrolled
at the Hospital Cajuru (Curitiba/PR, Brazil) from 2013 to 2015. Although we were able to confirm
previous observations of peripheral blood lymphopenia, no significant differences were detected in
NK cell levels in the BAL fluid of these patients. Overall, these findings strengthened the evidence
that peripheral blood lymphopenia is likely to be associated with cell death as a consequence of sepsis.
Keywords: natural killer (NK) cells; lung sepsis; lymphopenia; bronchoalveolar lavage (BAL)
1. Introduction
Sepsis is defined as life-threatening organ dysfunction caused by dysregulated host responses
to infection (as per the Third International Consensus definition for sepsis and septic shock) [1,2].
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Currently, sepsis is the tenth leading cause of death in high-income countries, accounting for more
than 210,000 annual deaths in the USA [3]. With an increasing incidence of sepsis of approximately 9%
each year and an increasing emergence of antibiotic resistance in microorganisms, which worsens the
efficacy of antibiotic treatment against sepsis [3,4], it is of great urgency to develop a more targeted
and efficient treatment strategy against sepsis. Sepsis is defined as the development of two or more
symptoms of systemic inflammatory response syndrome (SIRS) including abnormal thermal regulation,
atypical leukocyte count, tachycardia and rapid breathing [5,6]. Left untreated, sepsis may progress to
severe sepsis with the development of further complications such as multiple organ failure (MOF) [6].
These patients have an increased risk of subsequently advancing into septic shock—a state of persistent
hypotension despite intravenous fluid resuscitation due to acute circulatory failure. Both MOF and
septic shock lead to eventual death [5,6]. Despite being extensively studied, the pathogenesis of sepsis
and the contribution of cellular mediators of the inflammatory response remain poorly understood.
Recent studies have revealed that the pathogenesis of sepsis is not merely a result of an exacerbated
host inflammatory response in an attempt to clear invading pathogens. Combined dysregulation of
both pro- and anti-inflammatory responses of the host results in an overzealous release of cytokines
and chemokines known as the “cytokine storm”, resulting in the initial stage of SIRS [7–9]. Although a
localized inflammatory response is needed for the clearance of infection, failure of anti-inflammatory
mediators to control the inflammatory process can lead to endothelial dysfunction allowing further
invasion of pathogens into host organs [6]. In addition, patients surviving the initial SIRS stage were
discovered to frequently enter an immunosuppressive state during the later stage of sepsis, described
as a compensatory anti-inflammatory response syndrome (CARS) [10,11]. CARS is a consequence
of the body’s initial pro-inflammatory immune state during sepsis, leading to a defective adaptive
immune response rendering patients susceptible to secondary nosocomial infections responsible for
their death [12].
The innate immune system is a key player in the early stages of sepsis and various studies have
focused on the role of monocytes and macrophages in the pathogenesis of sepsis [13]. Natural killer
(NK) cells were initially described as innate lymphocytes with the ability to induce targeted cell
death in tumor cells and virus-infected cells by secreting granzymes (Grz) and perforin (PFP) [14–16].
The action of NK cells is regulated via activating and inhibitory receptors, which further divide NK
cells into different subtypes with different effector functions which have not yet been completely
described [17]. Apart from mediating cytotoxicity, NK cells have also been shown to have regulatory
functions on inflammation due to their ability to engage in reciprocal crosstalk with other immune
cells such as dendritic cells which provide the cytokine microenvironment required for NK cell
functions. This crosstalk is crucial in determining the response of NK cells, which subsequently
act on the development of the downstream immune response against infection by suppressing or
amplifying inflammation. NK cells produce an array of cytokines such as IFN-γ, GM-CSF and
TNF-α and chemokines such as CCL1, CCL2 and CCL5, which contribute to pathogen clearance but
also amplify the inflammatory response [17,18]. In addition, recent discoveries have implicated the
contribution of NK cells in the pathogenesis of sepsis due to their expression of innate sensors against
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs),
enabling them to directly recognize and respond to various pathogens [14,17].
Clinical research has identified that the number of circulating NK cells in the bloodstream
correlates inversely with patient survival, with significantly lower circulating NK cell numbers in
survivors of sepsis [19]. Additionally, the depletion or priming deficiency of NK cells in experimental
murine models of sepsis conferred greater survival benefits against sepsis [20–22]. This evidence
strongly suggests that NK cells participate in sepsis, and their circulating levels may be a biomarker
of mortality. The molecular mechanism by which NK cells participate in the pathogenesis of sepsis
has not been fully elucidated, and whether peripheral blood lymphopenia is linked to a rise in NK
cell levels in the infection sites has not being studied in patients. Here, we aimed to further study
NK cell–related lymphopenia with their respective levels in the bronchoalveolar lavage (BAL) fluid
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of lungs of infected patients maintained in the intensive care unit (ICU), and observed for the first




Twenty-three patients who were characterized as having severe sepsis had evidence of primary
infection in the lungs, and displayed clinical criteria of sepsis (fever or hypothermia, tachycardia (heart
rate > 90 bpm), tachypnea (respiratory rate > 20 mpm), leukocytosis (>12,000) or leukopenia (<4000),
BA stenosis (>10%)), or an increased sequential organ failure assessment (SOFA) score (two points or
more) associated with radiographic imaging identified by tomography and/or thorax radiography,
suggesting pulmonary damage due to infection. Patient characteristics are described in Table 1. Healthy
controls were patients who have previously undergone or have a currently established tracheostomy,
consisting of 10 trauma survivor patients (e.g., following a cerebrovascular accident, cranioencephalic
trauma, or polytrauma). These patients had prolonged orotracheal intubation until complete recovery,
and displayed no symptoms of infection/pneumonia or lung damage during the biopsy sampling.
Although healthy controls were subjected to peripheral blood and BAL fluid sampling, most of the
parameters displayed by these patients were not applicable for these controls. The sepsis patients have
all undergone mechanical ventilation and most had evidence of primary infection in the lungs (82.61%
with confirmed infection from the tracheal aspirate). Fifteen patients had Gram-negative bacterial
infections, while two displayed Gram-positive bacterial infections, and three had fungal infections and
three had undetermined microbial infections.
Table 1. Parameters of the studied patients.
Parameter Controls (n = 10) Sepsis (n = 23)
Age mean (SD) 49.4 (22.6) 59.17 (17.02)
Gender, n (%)
Male 8 (80%) 16 (69.57%)
Female 2 (20%) 7 (30.43%)
Body mass index, kg/m2, mean (SD) 28.13 (2.48) 26.14 (4.61)
Comorbidity, n (%) 14 (60.86%)
Hemorrhagic cerebrovascular accident N/A 4 (17.39%)
Other cerebrovascular accident (ischemia, or aneurysm) 4 (40%) 3 (13.04%)
COPD N/A 1 (4.35%)
Cancer N/A 1 (4.35%)
Lung N/A 4 (17.39%)
Liver failure N/A 1 (4.35%)
Skull/spine fracture N/A 4 (17.39%)
Polytrauma 6 (60%) 4 (17.39%)
Mechanic ventilation N/A 23 (100%)
Infection site
Urinary tract N/A 10 (43.48%)
Tracheal aspirate N/A 19 (82.61%)
Mechanic ventilation N/A 23 (100%)
Leukocytes, %/mm3, mean (SD) N/A 15,059.56 (10424.43)
SOFA, mean (SD) N/A 5.43 (2.27)
SAPS II, mean (SD) N/A 21 (9.95)
Length of stay in hospital, days, means (SD) N/A 39.82 (21.21)
Length of stay in ICU, days, mean (SD) N/A 18.78 (9.96)
In-hospital mortality number (%) N/A 7 (30.43%)
Gram-positive bacteria (%) N/A 2 (8.69%)
Gram-negative bacteria (%) N/A 15 (65.21%)
Fungus N/A 3 (13.04%)
Undetermined microbial infection N/A 3 (13.04%)
COPD, chronic obstructive airways disease; N/A, not applicable, SOFA, sequential organ failure assessment; SAPS,
simplified acute physiology score.
2.2. Pro-Inflammatory Cytokine Profiling in Bronchoalveolar Lavage (BAL) Fluid Samples after Sepsis
Multiple cytokine patterns were associated with a systemic response in sepsis [23]. To characterize
the pro-inflammatory cytokine content in the BAL fluid and in peripheral blood, we screened the
samples with a customized Th1/Th2 cytokine detection array. Consistent with previous studies [24],
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IL-6 was significantly upregulated in the plasma samples from sepsis patients, as well as in the BAL
fluid samples, while minimal and insignificant detection of IL-2 and IL-4 was observed (Figure 1).
In contrast, we failed to observe a significant increase in other pro-inflammatory cytokines such as
IFN-γ and TNF-α in these clinical settings.
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Figure 1. Cytokine profiling of plasma (represented by Bd) and bronchoalveolar lavage (BAL) fluid
from sepsis patient samples. Cytokine assessment was performed on plasma or BAL fluid samples
which were collected within 48 h of clinical classification of severe sepsis and ICU admission. IFN-γ,
IL-2, IL-4, IL-6, and TNF-α levels are represented as pg/mL in mean ± SEM, with all data from
individual controls or patients. Statistical analysis was performed using the Mann-Whitney test, where
** p < 0.01, or *** p < 0.001 were considered for statistical significance.
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2.3. Natural Killer (NK) Cell Subsets Are Reduced in Peripheral Blood but Unchanged in BAL Fluid Samples
after Sepsis
We next assessed the lymphocytic composition of these samples. The numbers of CD3neg
and CD56bright or CD56dim NK cell subsets in the peripheral blood and BAL fluid samples from
sepsis patients and healthy controls were determined and compared. Representative flow cytometry
results from each group are shown in Supplementary Figure S1, and the median and scattering plot
comparisons of each group are shown in Figure 2A (for CD56bright subset) and 2B (for CD56dim subset).
In agreement with previous studies [19,25,26], both NK cell subsets were clearly reduced in number in
the peripheral blood compartment of sepsis patients, in comparison to healthy controls. In contrast,
no differences were observed in these cell levels in the BAL fluid samples.
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Figure 2. NK cell subset assessment in the peripheral blood or BAL fluid of sepsis patients.
(A) Peripheral blood (number per 50 µL blood) and BAL fluid (number recovered from the total
BAL lavage) CD56bright, CD3neg, 7AADneg cells were quantified by flow cytometry. (B) Peripheral
blood (number per 50 µL blood) and BAL fluid (number recovered from the total BAL lavage) CD56dim,
CD3neg, 7AADneg cells were quantified by flow cytometry. Statistical analysis was performed by
one-way ANOVA followed by the Tukey post hoc test, where * p < 0.05, or *** p < 0.001 were considered
for statistical significance.
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2.4. T CD4 and T CD8 Cell Levels Are Also Reduced in the Peripheral Blood, but Not in the BAL Fluid of
Sepsis Patients
To compare whether reduced NK cell levels in the peripheral blood and sustained NK cell levels
in the BAL fluid are comparable with other lymphocytic subset levels, also described as lymphopenic
in sepsis [25], we performed additional staining to determine T CD4 and T CD8 cell levels in the
same samples. Representative flow cytometry results from each group are shown in Supplementary
Figure S2, and the median and scattering plot comparisons of each group are shown in Figure 3A (for
T CD4 cell subset) and Figure 3B (for T CD8 cell subset). In agreement with the NK cell levels, other
lymphocytes such as T cells also seem to suffer from the global lymphocytic lymphopenia previously
observed in the peripheral blood of sepsis patients. However, the BAL fluid levels also remained
unchanged for these cell subsets, suggesting that the lung microenvironment does not mimic the
lymphopenia observed in the peripheral circulation or recruit lymphocytes in response to infection.
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Figure 3. T cell subset assessment in the peripheral blood or BAL fluid of sepsis patients. (A) Peripheral
blood (number per 50 µL blood) and BAL fluid (number recovered from the total BAL lavage)
CD4+, CD3+, CD8neg, 7AADneg cells were quantified by flow cytometry. (B) Peripheral blood
(number per 50 µL blood) and BAL fluid (number recovered from the total BAL lavage) CD4neg,
CD3+, CD8+, 7AADneg cells were quantified by flow cytometry. Statistical analysis was performed
by one-way ANOVA followed by the Tukey post hoc test, where *** p < 0.001 was considered for
statistical significance.
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3. Discussion
Our current study aimed to further characterize the immune status of NK cells in both the
peripheral blood and the BAL fluid of patients with bacterial pneumonia. Consistent with previous
reports from our group and others [25,26], we observed both NK and T cell lymphopenia in the
peripheral blood of sepsis patients. The site of infection as well as both systemic and local variables
were historically considered in scores that predict patient survival [27]. Sample acquisition of peripheral
blood for studying immune cells in sepsis patients is commonly performed due to the convenience
of acquiring these types of samples. However, due to the nature of the bacterial insult, the type of
leukocytes found at the site of infection may be significantly different from the peripheral blood cells
due to the complex and compartmentalized inflammatory response in sepsis [28]. In addition, a recent
study demonstrated that the local microenvironment controls the compartmentalization of NK cell
responses during experimental systemic inflammation [9]. To date, our study was the first to compare
these cell populations simultaneously in both peripheral blood and BAL fluid samples from sepsis
patients, and to measure these cell levels systemically and at respective infection sites. Interestingly,
both NK cells and other lymphocytes such as T CD4 and T CD8 cells displayed blood lymphopenia,
while no altered levels of these cell subsets were observed in the BAL fluid samples.
Lymphopenia during sepsis is a clinically described phenomenon which is hypothesized to
result either because of trafficking to the infection sites, or cell death. Hotchkiss and colleagues
previously demonstrated that lymphopenia is a consequence of lymphocyte apoptosis during sepsis,
and that prevention of lymphocyte death improves survival in mice [29]. The same group also reported
that administration of interleukin-(IL-)7 and IL-15 reversed lymphocyte apoptosis and improved
sepsis survival in experimental mice models [30,31]. The same group also showed that in patients,
persistent lymphopenia is a predictor of mortality and sepsis-induced immunosuppression [32]. Based
on these findings, new clinical trials studying the administration of recombinant IL-7 are currently
being evaluated in an attempt to reverse lymphopenia and sepsis-induced immunosuppression
in sepsis patients (ClinicalTrials.gov identifier: NCT02640807 and NCT02797431). In contrast
to the cell death–induced lymphopenia hypothesis, Herzig and colleagues demonstrated that in
experimental peritoneal sepsis, murine NK cells migrate into the peritoneal cavity via a chemokine
(C-X-C motif) receptor 3 (CXCR3)-induced mechanism, resulting in peripheral blood lymphopenia.
This suggests that it may be a consequence of chemotaxis to the infection site [33], as well as the
inflammation/cytokine-induced activation state of both lymphocytes and endothelial cells [34]. One
possible hypothesis, which may explain peripheral blood lymphopenia but unchanged cell levels
in other compartments, is that cellular activation may result in increased cell adhesion molecules
which anchor specific lymphocytes to the endothelial wall. This possibility could result in less soluble
lymphocytes in blood, which would resemble a peripheral blood lymphopenia scenario.
Although experimental sepsis is a powerful tool used to understand the mechanisms of immune
responses in the process of this syndrome, the immune response variability to pathogen-associated
molecular patterns (PAMPS) between different species can vary by over 10,000-fold between mice and
humans [35]. In addition, a subsequent systematic study which evaluated how well murine models
mimic human sepsis revealed poor translation of genomic responses between species [36]. Our study
supports the hypothesis that lymphopenia in sepsis is likely to be associated with apoptosis-induced
cell death during the exaggerated inflammatory event [37]. However, our study was limited to BAL
fluid sampling, and there is a possibility that using samples from homogenates of lung biopsies
could reveal a different outcome. In this study, we further extended the concept of NK cell levels in
different compartments in sepsis patients, and demonstrated that blood lymphopenia is not necessarily
associated with increased levels of these cells in the BAL fluid of lung-related sepsis patients.
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4. Experimental Section
4.1. Clinical Samples
Intensive care unit (ICU) patients with a confirmed diagnosis of pneumonic sepsis, and
healthy controls undergoing post surgery-related tracheostomy monitoring, were recruited into an
established, ethically-approved study investigating the natural history and pathogenesis of sepsis in
the Hospital Cajuru, Curitiba/PR, Brazil. The study was approved by the regional ethics committee
of the Hospital Cajuru and Pontifícia Universidade Católica do Paraná, Curitiba/PR, Brazil (CAAE:
16930013.0.0000.0102, Number: 439.881, Date of approval: 9 October 2013), and Federal University of
Parana, Curitiba/PR, Brazil (Number: 398.997, Date of approval: 11 September 2013). In addition, a
written informed consent to participate in the study was obtained for each patient, or if not possible,
from the patient’s next-of kin. Peripheral blood and BAL fluid samples were acquired from 23 patients
within 48 h post ICU admission. Patients were recruited according to sepsis classification, where
any subject with cancer, HIV, undergoing tissue transplantation or chronic corticosteroid or other
immunosuppressive medication therapy were excluded. Healthy controls undergoing prolonged
orotracheal intubation were monitored by routine bronchoscopy to survey lung status. BAL fluid was
collected, as previously described [38,39], from segmental bronchus from medium lobe, excluding any
subject with active lung disease at the time of the exam. BAL fluid samples were promptly placed in
silicone tubes connected to the aspiration system through the vacuum suction system. Blood samples
were also acquired from the same patients and healthy controls’ peripheral veins in heparin-containing
collection tubes. All samples were immediately sent for analysis.
Individuals with confirmed bacterial infection were classified as patients with sepsis. Individuals
in whom infection was not confirmed were classified as Systemic Inflammatory Response Syndrome
(SIRS) patients and were not included in the analysis. Patient samples were compared to samples from
10 healthy volunteers and all samples were collected at the Hospital Cajury (Serviço de Endoscopia
Respiratória e Cirurgia Torácica do Hospital Universitário Cajuru), Curitiba/PR, Brazil. All fresh
samples were processed for flow cytometry, and cytokine analysis was performed from frozen BAL
supernatant and plasma, maintained at −80 ◦C until the day of analysis.
4.2. Reagents
Labeled antibodies against the following antigens were used: anti-CD3 (clone UCHT1), anti-CD56
(clone HCD56), anti-CD19 (clone HIB19), anti-CD20 (clone 2H7), anti-CD4 (clone RPA-T4), anti-CD8
(clone SK1). All antibodies, Fc block reagent (anti-CD16/32) and 7-AAD, used as viability dye, were
purchased from Biolegend (San Diego, CA, USA). Cytokines were measured by flow cytometry using
the Human Th1/Th2 Cytometric Bead Array Kit (BD Bioscience, San Jose, CA, USA).
4.3. Flow Cytometry
Cell surface antigens were labeled by diluting antibodies in staining buffer at the concentration
suggested by the manufacturers. All samples were processed as previously described by our group [26].
All flow cytometry data was acquired via a FACS Calibur (BD Biosciences, San Jose, CA, USA), and
analyzed using the Flow Jo software (Tree Star, Ashland, OR, USA). Cell numbers were determined
as previously described [26], by gating the respective lymphocyte subsets using the FACS Calibur
cytometer, allowing for absolute counting. All cytokines from sepsis patients and healthy control
samples were detected using Cytometric Bead Array (CBA) technology according to the manufacturer’s
instructions using a FACS Verse cytometer to acquire samples, and FCAP Array software to analyze
them (BD Biosciences, San Jose, CA, USA).
4.4. Statistical Analysis
Statistical analysis was achieved using Graph Pad Prism Software (GraphPad, La Jolla, CA, USA).
Data was considered to be statistically significant where the p-value was equal to or less than 0.05.
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Statistical tests used were the Mann Whitney test, or one-way ANOVA with Tukey’s post hoc test for
group comparison.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/616/s1.
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